These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 15951730)
1. New drugs. Waters L; Nelson MR J HIV Ther; 2005 Mar; 10(1):16-8. PubMed ID: 15951730 [No Abstract] [Full Text] [Related]
2. Aspects of successful drug discovery and development. Pauwels R Antiviral Res; 2006 Sep; 71(2-3):77-89. PubMed ID: 16828174 [TBL] [Abstract][Full Text] [Related]
3. The emergence of peptides as therapeutic drugs for the inhibition of HIV-1. Huther A; Dietrich U AIDS Rev; 2007; 9(4):208-17. PubMed ID: 18219364 [TBL] [Abstract][Full Text] [Related]
4. Pipeline update: short notes on new anti-HIV drugs in development. Proj Inf Perspect; 2006 Oct; (42):11-6. PubMed ID: 17162806 [No Abstract] [Full Text] [Related]
5. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs. Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730 [No Abstract] [Full Text] [Related]
6. Adherence to antiretroviral therapy: how much is enough? Gulick RM Clin Infect Dis; 2006 Oct; 43(7):942-4. PubMed ID: 16941381 [No Abstract] [Full Text] [Related]
8. Anti-HIV agents. New drugs in the pipeline. TreatmentUpdate; 2003; 15(2):1-3. PubMed ID: 12691045 [No Abstract] [Full Text] [Related]
9. Current developments in HIV chemotherapy. Meadows DC; Gervay-Hague J ChemMedChem; 2006 Jan; 1(1):16-29. PubMed ID: 16892329 [TBL] [Abstract][Full Text] [Related]
10. New developments in HIV drug resistance. Cane PA J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018 [TBL] [Abstract][Full Text] [Related]
11. Update of the drug resistance mutations in HIV-1: 2007. Johnson VA; Brun-Vézinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD Top HIV Med; 2007; 15(4):119-25. PubMed ID: 17720996 [No Abstract] [Full Text] [Related]
12. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784 [TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy roundup from CROI. Report on newer drugs in development and some already approved drugs. Berry J Posit Aware; 2008; 19(3):20-3. PubMed ID: 18724440 [No Abstract] [Full Text] [Related]
14. Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E Bioorg Med Chem; 2007 Feb; 15(4):1725-31. PubMed ID: 17178227 [TBL] [Abstract][Full Text] [Related]
15. HIV type 1 integrase inhibitors: from basic research to clinical implications. Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients. Soriano V Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872 [TBL] [Abstract][Full Text] [Related]
17. HIV treatment decisions and transmitted drug resistance. Little SJ; Smith DM Clin Infect Dis; 2005 Jul; 41(2):233-5. PubMed ID: 15983921 [No Abstract] [Full Text] [Related]
18. Waiting in the wings: more new drugs. Sharp M Posit Aware; 2003; 14(6):33-4. PubMed ID: 14743792 [No Abstract] [Full Text] [Related]
19. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. Tabarrini O; Massari S; Daelemans D; Stevens M; Manfroni G; Sabatini S; Balzarini J; Cecchetti V; Pannecouque C; Fravolini A J Med Chem; 2008 Sep; 51(17):5454-8. PubMed ID: 18710207 [TBL] [Abstract][Full Text] [Related]
20. Detection and significance of minority quasispecies of drug-resistant HIV-1. Metzner KJ J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210 [No Abstract] [Full Text] [Related] [Next] [New Search]